Los Angeles Capital Management & Equity Research Inc. Has $80.99 Million Stake in Allergan PLC. (AGN)
Los Angeles Capital Management & Equity Research Inc. grew its holdings in shares of Allergan PLC. (NYSE:AGN) by 18.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 333,184 shares of the company’s stock after purchasing an additional 51,725 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.10% of Allergan PLC. worth $80,994,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Jacobi Capital Management LLC raised its stake in Allergan PLC. by 4.9% in the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after acquiring an additional 22 shares during the last quarter. JNBA Financial Advisors raised its stake in Allergan PLC. by 2.5% in the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after acquiring an additional 12 shares during the last quarter. Pacific Center for Financial Services raised its stake in Allergan PLC. by 805.1% in the 1st quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after acquiring an additional 475 shares during the last quarter. Hudock Capital Group LLC raised its stake in Allergan PLC. by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after acquiring an additional 2 shares during the last quarter. Finally, Ropes Wealth Advisors LLC raised its stake in Allergan PLC. by 31.0% in the 1st quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock worth $137,000 after acquiring an additional 136 shares during the last quarter. Hedge funds and other institutional investors own 82.02% of the company’s stock.
A number of brokerages recently issued reports on AGN. Vetr upgraded Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a research note on Monday, June 26th. BidaskClub lowered Allergan PLC. from a “sell” rating to a “strong sell” rating in a research note on Friday, August 25th. Citigroup Inc. restated a “buy” rating and issued a $280.00 target price on shares of Allergan PLC. in a research note on Wednesday. Royal Bank Of Canada set a $284.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research note on Monday, June 12th. Finally, Mizuho restated a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research note on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $273.34.
COPYRIGHT VIOLATION WARNING: “Los Angeles Capital Management & Equity Research Inc. Has $80.99 Million Stake in Allergan PLC. (AGN)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/24/los-angeles-capital-management-equity-research-inc-has-80-99-million-stake-in-allergan-plc-agn.html.
Shares of Allergan PLC. (NYSE AGN) opened at 204.65 on Friday. The company has a 50-day moving average price of $229.79 and a 200 day moving average price of $236.07. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The firm has a market capitalization of $68.42 billion, a PE ratio of 6.24 and a beta of 1.18.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the company posted $3.35 earnings per share. On average, equities analysts expect that Allergan PLC. will post $16.26 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.37%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
Allergan PLC. Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.